New exciting therapies for neuroendocrine tumours include the introduction of RET inhibitors for medullary thyroid cancer and belzutifan for metastatic pancreatic neuroendocrine tumours. We were delighted to speak with our editorial board member Prof. Ashley Grossman (University of Oxford, Oxford, UK) around this year’s research highlights in these topics and what to look out for in 2023.
Questions
- What are the key clinical highlights from 2022 in the field of neuroendocrinology? (0:08)
- What are the hot topics and latest research you are looking forward to exploring in 2023? (1:13)
Disclosures: Ashley Grossman has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
